HSPA12B and stroke disorder: As shown in Figure 9A, pre‐administration with L‐NAME decreased neurological scores significantly in HSPA12B Tg mice within 21 days post‐stroke compared with the time‐matched HSPA12B Tg mice without L‐NAME administration (P < 0.01 or 0.05), respectively.